Hidetaka Kawabata's research while affiliated with Toranomon Hospital and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (88)
Background Chemotherapy is crucial for hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, and its survival benefit may outweigh adverse events. Oncotype DX (ODX) assesses this balance; however, it is expensive. Using nomograms to identify cases requiring ODX may be economically beneficial. We aimed to...
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with poor prognosis and limited therapeutic strategies, lacking expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. We previously demonstrated that estrogen responsive finger protein (Efp)/TRIM25 functions as a ubiquitin...
The Chemotherapy-induced Alopecia Distress Scale (CADS) is a patient-reported outcome measure for assessing distress associated with Chemotherapy-induced alopecia (CIA). This study aimed to confirm the psychometric validity of the Japanese version of the CADS (CADS-J).
A total of 132 patients with breast cancer who developed CIA were asked to compl...
Background
Hormone receptor (HR)-positive breast cancer is a disease for which no immune checkpoint inhibitors have shown promise as effective therapies. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors synergistically increased the effectiveness of antiprogrammed cell death protein-1 (anti-PD-1)/programmed death-ligand 1 (PD-L1) antibodies in p...
Objective:
We occasionally observed internal mammary lymph node metastases of breast cancer in a clinical setting. However, unlike a standard treatment in axillary metastasis, surgical resection for internal mammary lymph node metastasis is not prevalent because of unclear safety and benefits. Thus, we aimed to evaluate the diagnostic ability and...
Background:
Invasive lobular carcinoma (ILC) grows diffusely in a single-cell fashion, sometimes presenting only subtle changes in preoperative imaging; therefore, axillary lymph node (ALN) metastases of ILC are difficult to detect using magnetic resonance imaging (MRI). Preoperative underestimation of nodal burden occurs more frequently in ILC th...
Background: Positron emission tomography/computed tomography (PET/CT) and magnetic resonance imaging (MRI) are useful imaging modalities for the preoperative nodal staging in breast cancer; however, clinical evidence demonstrating the diagnostic accuracy of the combination of PET/CT and MRI is limited. The purpose of this study is to establish a cl...
Background: We have conducted a phase II trial (WJOG9917B) to evaluate efficacy of triple therapy with nivolumab, paclitaxel and bevacizumab in patients (pts) with HER2-negative metastatic breast cancer (MBC). Although soluble CD163 has been reported as a potential biomarker for predicting the efficacy of nivolumab in melanoma, however the data is...
Background Previously, we reported the clinical outcomes of the combination of anti-PD-1 Ab, cyclin-dependent kinase 4/6 inhibitors, and endocrine therapy (ET) in patients with ER positive/HER2 negative advanced breast cancer in SABCS2020; biomarker analysis has been performed to provide insight into the hepatotoxicy frequently observed in the stud...
Background:
Solitary fibrous tumors (SFT) are uncommon mesenchymal neoplasms which can arise in any anatomical location. Pleural SFTs have been most frequently documented; however, breast SFT is an exceedingly rare entity and seldom present in male breast, with only 8 previously reported cases. Recently, STAT6 immunostaining was considered to be a...
Recent advances in RNA studies have revealed that functional long noncoding RNAs (lncRNAs) contribute to the biology of cancers. In breast cancer, estrogen receptor α (ERα) is an essential transcription factor that primarily promotes the growth of luminal-type cancer, although only a small number of lncRNAs are identified as direct ERα targets and...
Purpose
Positron emission tomography/computed tomography (PET/CT) and magnetic resonance imaging (MRI) are useful for detecting axillary lymph node (ALN) metastasis in invasive ductal breast cancer (IDC); however, there is limited clinical evidence to demonstrate the effectiveness of the combination of PET/CT plus MRI. Further axillary surgery is n...
Background: We have conducted a phase II trial (NEWBEAT) to evaluate efficacy of triple therapy with nivolumab, paclitaxel and bevacizumab in patients (pts) with HER2-negative MBC. Immunological status and response to immune checkpoint inhibitor would be different between recurrent and de novo stage IV breast cancer (BC), however the data is limite...
The purpose was to explore potential biomarkers of the efficacy and toxicity of triple therapy of nivolumab, bevacizumab and paclitaxel in patients with HER2-negative metastatic breast cancer (MBC). Tumor tissues before treatment and blood samples at pretreatment, during and after treatment were collected. The serum samples were used to measure the...
Background:
Preclinical models revealed potential synergistic effects of programmed cell death-1 inhibitors and anti-vascular endothelial growth factor (VEGF) antibodies. Therefore, we investigated the use of nivolumab, bevacizumab, and paclitaxel triple therapy for metastatic breast cancer.
Methods:
This phase 2, multicentre, single-arm study (...
Breast cancer is the most common cancer type among women worldwide. The majority of breast cancer expresses estrogen receptor (ER) and endocrine therapy is a standard treatment of ER-positive breast cancer. However, development of the therapy resistance is still a major challenge and thus new therapeutic approaches are needed. Here we show that an...
e12576
Background: From the results of ACOSOG Z0011, IBCSG23-01 and AMAROS trials, axilla surgery in node-positive breast cancer (BC) tends to be less invasive with sentinel node biopsy (SNB) followed by adjuvant therapy and regional node irradiation (RNI). However, optimized axilla treatment including SNB without RNI is still debated. The Japanese...
Tripartite motif (TRIM) family proteins are involved in various biological processes and the pathophysiology of cancers. However, the roles of TRIM39, a TRIM family member, in breast cancer is not well-understood. Here, we performed immunohistochemical study of TRIM39 protein in clinical estrogen receptor-positive (ER⁺) breast cancer tissues from 1...
Purpose
The sequence of taxanes (T) followed by anthracyclines (A) as neoadjuvant chemotherapy has been the standard of care for almost 20 years for locally advanced breast cancer (LABC). Sequential administration of eribulin (E) following A/T could provide a greater response rate for women with LABC.
Methods
In this single-arm, multicenter, Phase...
Octamer transcription factor 1 (OCT1) is a transcriptional factor reported to be a poor prognostic factor in various cancers. However, the clinical value of OCT1 in breast cancer is not fully understood. In the present study, an immunohistochemical study of OCT1 protein was performed using estrogen receptor (ER)-positive breast cancer tissues from...
Purpose
To investigate clinical usefulness of eribulin-based neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) patients.
Methods
Patients in group A (aged < 65 years with homologous recombination deficiency, HRD, score ≥ 42, or those at any age with germline BRCA mutation, gBRCAm) were randomized to 4 cycles of paclitaxel plus carbo...
Purpose
The sequence of taxanes (T) followed by anthracyclines (A) as neoadjuvant chemotherapy (NAC) has been the standard of care for almost 20 years for locally advanced breast cancer (LABC). Sequential administration of eribulin (E) following A/T could provide a greater response rate for women with LABC.
Methods
In this single-arm, multicenter,...
Purpose
The sequence of taxanes (T) followed by anthracyclines (A) as neoadjuvant chemotherapy (NAC) has been the standard of care for almost 20 years for locally advanced breast cancer (LABC). Sequential administration of eribulin (E) following A/T could provide a greater response rate for women with LABC.
Methods
In this single-arm, multicenter,...
p> Background: Synergistic antitumor effect of combined anti-PD-1 antibody and anti-VEGF agent has been expected, based on previous preclinical data. We have conducted NEWBEAT trial to evaluate efficacy of triple combination regimen of nivolumab + paclitaxel + bevacizumab in patients (pts)with HR+ HER2- MBC or metastatic TNBC, and clinical results...
A 64-year-old woman was referred to our hospital with a palpable mass in her left breast. Mammography and ultrasonography showed a 40-mm, well-circumscribed mass with axillary lymphadenopathy. A core needle biopsy of the mass was done, which was diagnosed as adenocarcinoma. PET-CT scan showed a large, 80-mm mass with abnormal FDG accumulation in th...
Mammary-type myofibroblastoma (MTMF) is a relatively rare benign mesenchymal neoplasma that has been reported in diverse body regions. In this study, we report three cases of MTMF in the breast. Although image findings in each case depicted a variety of images, all showed a benign pattern. Histopathologically, the tumors consisted of spindle cells...
Background
We previously identified Efp as an estrogen induced gene, and showed that the positive immunoreactivity of Efp is a poor prognostic factor for breast cancer patients. We also demonstrated that Efp has distinctive roles in innate immunity by activating pattern recognition receptor RIG-I. The clinical value of RIG-I protein expression in b...
We previously reported that a strong immunoreactivity of tripartite motif‐containing 44 (TRIM44) predicts the poor prognosis of patients with invasive breast cancer, and proposed that TRIM44 activates nuclear factor‐κB (NF‐κB) signaling as a causative mechanism. In the present study, we examined the clinicopathological roles of A20, which is known...
Background:
Sodium channels located in the dorsal root ganglion, particularly Nav1.7 and Nav1.8, encoded by SCN9A and SCN10A, respectively, act as molecular gatekeepers for pain detection. Our aim was to determine the association between TIPN and SCN9A and SCN10A polymorphisms.
Methods:
Three single nucleotide polymorphisms (SNPs) in SCN9A and t...
Endocrine therapy is standard treatment for estrogen receptor (ER)-positive breast cancer, yet long-term treatment often causes acquired resistance, which results in recurrence and metastasis. Recent studies have revealed that RNA-binding proteins (RBP) are involved in tumorigenesis. Here, we demonstrate that PSF/SFPQ is an RBP that potentially pre...
[Background] Tripartite motif-containing (TRIM) proteins typically function as E3 ubiquitin ligases and involved in many biological processes including cancer biology. We previously reported that TRIM25/Efp which stimulated the degradation of a negative cell-cycle regulator, 14-3-3 sigma,is a poor prognostic factor for breast cancer patients (Natur...
A 49-year-old woman was referred to the emergency department with the chief complaint of recurrent vomiting. She had also noticed a left breast mass 8 months prior to the visit. The patient was diagnosed with left breast carcinoma, duodenal stenosis, and right urinary duct stenosis. Although distant metastasis of breast carcinoma to the peritoneum...
The majority of breast cancers are primarily hormone-sensitive and could be managed by endocrine therapy, although therapy-resistant or hormone-refractory cancers need alternative treatments. Recently, increasing attention is being paid to RNA-binding proteins (RBPs) in cancer pathophysiology. The precise role of RBPs in breast cancer, however, rem...
Background:
While denosumab has been shown to prevent skeletal-related events in patients with bone metastasis, there is a concern that it may cause atypical femoral fracture (AFF). While AFF has been reported in patients with osteoporosis receiving denosumab, data are scarce in the context of AFF occurring in patients with bone metastasis receivi...
Acquired endocrine therapy resistance is a significant clinical problem for breast cancer patients. Nowadays, increasing attention has been paid to long non-coding RNA (lncRNA) as a critical modulator for cancer progression. Based on RNA-sequencing data of breast invasive carcinomas in The Cancer Genome Atlas database, we identified thymopoietin an...
Purpose: Distant recurrence following metastasis is a major cause of cancer-associated death. Interfering spread and re-growth of the disseminated tumor cells, which could be cancer stem-like cells (CSCs) via EMT, must be greatly helpful for improving prognosis of cancer patients. However, little is known about the molecular mechanisms underlying t...
Purpose: Distant recurrence following metastasis is a major cause of cancer-associated death. Interfering spread and re-growth of the disseminated tumor cells, which could be cancer stem-like cells (CSCs) via EMT, must be greatly helpful for improving prognosis of cancer patients. However, little is known about the molecular mechanisms underlying t...
Background:
For human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) with progression on trastuzumab-based therapy, continuing trastuzumab beyond progression and switching to lapatinib combined with chemotherapy are both valid options. We conducted an open-label, randomized phase II trial to compare the efficacy...
[Background]
Many of the tripartite motif (TRIM) proteins, like Efp/TRIM25 which was identified by our group previously (Nature 417, 871-875, 2002), function as E3 ubiquitin ligases, and are thought to be involved in various physiological and pathological processes such as immunity and oncogenesis. In regard to tripartite motif containing 44 (TRIM4...
IntroductionAlthough tamoxifen (TAM) plus ovarian function suppression (OFS) is considered as a standard adjuvant treatment for premenopausal women with hormone receptor-positive breast cancer, the optimal duration of OFS has not yet been established. This retrospective study was designed to assess the duration of OFS and the impact of the duration...
Many of the tripartite motif (TRIM) proteins function as E3 ubiquitin ligases and are assumed to be involved in various events, including oncogenesis. In regard to tripartite motif-containing 44 (TRIM44), which is an atypical TRIM family protein lacking the RING finger domain, its pathophysiological significance in breast cancer remains unknown. We...
Purpose:
Whether age and inter-individual variability of pharmacogenetics are risk factors for paclitaxel-induced peripheral neuropathy (PIPN) is inconclusive. This study was conducted to evaluate the influence of previously investigated single nucleotide polymorphisms (SNPs) and age, using genotype data from a prospective study of paclitaxel-rela...
Introduction
In metastatic breast cancer (MBC), discordant expression levels of the human epidermal growth factor receptor 2 (HER2) have been noted between primary tumors (PT) and matched metastatic lesions. Reassessment of HER2 status during treatment decisions in patients with advanced disease might help to optimize outcome. Circulating tumor cel...
Background: Although tamoxifen (TAM) plus ovarian function suppression (OFS) is one of standard adjuvant treatments in premenopausal women with hormone receptor-positive breast cancer, the optimal duration of OFS has not been clearly established.
Patients and Methods: We retrospectively reviewed data of premenopausal patients with breast cancer, wh...
Background: Oncotype DX(ODX) is a clinically validated, commercially available multi-gene assay that provides prognostic and predictive information in estrogen receptor(ER)-positive, Her2-negative breast cancer. Because health care system does not cover this expensive assay in many countries, physicians and researchers try to use routine histopatho...
Background: Eribulin dose modification is recommended in breast cancer patients with liver dysfunction evaluated by Child-Pugh classification. However, the little information on initial dose modification for the patients with Child-Pugh A liver dysfunction is available.
Methods: We retrospectively reviewed breast cancer patients with Child-Pugh A l...
For patients with HER2-positive breast cancer, the prognostic impact of pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) is unclear when stratified by hormonal receptor (HR) status; however, the impact of pCR on survival when stratified by hormonal receptor (HR) status is uncertain.
This multicenter retrospective study invest...
We investigated the disease-free survival (DFS) of HER2-positive primary breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab, as well as predictive factors for DFS and pathologic response. Data from 829 female patients treated between 2001 and 2010 were collected from 38 institutions in Japan. Predictive factors were evalu...
BACKGROUND:
Addition of trastuzumab to neoadjuvant chemotherapy (NAC) improved pathologic complete response (pCR) rate in HER2-positive breast cancer. Although recent trials have shown favorable prognosis with NAC plus trastuzumab, clinicopathological factors to predict the outcome have not been fully understood. The aim of this study was to invest...
Background:
This retrospective study aimed to determine whether adverse events are more common in docetaxel followed by cyclophosphamide (TC) as compared to the reverse infusion order (rTC).
Methods:
A retrospective analysis was undertaken at a single institution for 92 consecutive cases treated with TC or rTC for stage I-III breast cancer in a...
Background: Hepatitis C virus (HCV) infection is one of the major causes of chronic liver disease, and more than 880,000 people are estimated to be infected with HCV in Japan. Little information is available on the outcomes of HCV during chemotherapy for solid tumors, and the impact of HCV infection on toxicity of chemotherapy is unknown.
Materials...
e11519
Background: Current approaches of neoadjuvant endocrine therapy (NAET) are focusing on biomarker analysis of the diagnostic specimens however inadequate response occurs in 5-10% of patients treated. It has been reported hormone resistance may predict Ki67 level after treatment than ΔKi67. Much less is known about the difference between Ki67...
The aims of the present study were as follows: (i) to clarify the proportion of women who experience psychological distress during breast cancer diagnosis and (ii) to identify the predictors of psychological distress related to the diagnostic process.
This was a longitudinal prospective study of women who required further breast examination. Questi...
Background: The current standard treatment of primary systemic therapy (PST) in HER2 positive breast cancer is anthracyclines (A) and/or taxanes combined with trastuzumab (H) which demonstrates high pathological complete response (pCR). The pCR is considered as a predictive marker of prognosis although results are slightly different depending on th...
591
Background: Current approaches of neoadjuvant endocrine therapy (NAET) are focusing on biomarker analysis of the diagnostic specimens. One of the important things in neoadjuvant treatment is to determine the in-vivo responsiveness to the agent. Little is known regarding biomarker changes in specific agents and the association with biomarker cha...
Nodular fasciitis of the breast is a rare, benign, soft-tissue tumor that can clinically and radiologically mimic invasive ductal carcinoma. A 25-year-old woman presented with a palpable lesion in the lower inner aspect of the left breast. Radiologically, breast carcinoma could not be excluded. On examination of the core needle biopsy, the tumor wa...
The US oncology 9735 study showed the superior result of TC (docetaxel/cyclophosphamide) over AC (doxorubicin/cyclophosphamide), and now TC has been widely adopted for the treatment of early breast cancer. But in Japan there are few data on the safety and tolerability of this regimen. From January 2007 to April 2009, we treated 51 early breast canc...
Few experts can deal appropriately with metastatic bone tumors in the present situation. We developed a questionnaire about zoledronic acid for doctors with several specialties, and analyzed the differences in treatment strategy among various doctors retrospectively. Breast surgeons, have used zoledronic acid appropriately based on accurate knowled...
e11600
Background: Precise assessment of HER-2 is critical in breast cancers and predicts benefit of trastuzumab (T). Although subset analysis of CALGB 9840 suggests benefit in FISH-negative patients with chromosome 17 polysomy (C17), clinical significance of C17 in FISH-positive patients is still less known. To analyze the epidemiologic feature of...
3503
Background: One of the important mechanisms that trastuzumab (TZ) inhibits the growth of Her-2 overexpressing breast cancer cells is the activation of a host tumor response via antibody-dependent cell-mediated cytotoxicity (ADCC). Although paclitaxel (PTX) has a synergistic effect in combination with TZ, whether the ADCC is enhanced by PTX is...
Citations
... In the case of the failure of first-line endocrine treatment, the sequential use of hormone therapies remains the backbone of metastatic HR+ breast cancer management. However, during the last decade, the therapeutic landscape for advanced, endocrine-resistant breast cancer has changed with the incorporation of novel targeted therapies including phosphatidylinositol-3-kinase/Akt and the mammalian target of rapamycin (PIK3CA/AKT/mTOR) signaling pathway inhibitors [10][11][12], next-generation selective estrogen receptor (ER) degraders (SERDs) [13][14][15] and poly ADP ribose polymerase (PARP) inhibitors [16,17], as well as novel treatment approaches, such as ER proteolysis-targeting chimeras (PROTACs) [18] or immunotherapy [19][20][21][22], which are currently being evaluated as monotherapies or in different combinations. Until recently, subsequent therapeutic choices for endocrine-resistant metastatic breast cancer were limited to sequential single-agent chemotherapy, usually associated with low response rates [23][24][25]. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/293347282440193-1446950850154_Q64/Junji-Tsurutani.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/819402610073601-1572372214105_Q64/Toshimi-Takano.jpg)
... Of 34 patients identified with PET avidity in IMLNs, 11 patients underwent VATs resection of IMLNs without any complications noted. However, patients required an average 2-3-day hospital stay following this procedure (23). Importantly, without strong evidence that retrieval of involved IMLNs impacts oncologic outcomes, there would not be a benefit to removal that would outweigh the associated surgical risk. ...
... Indeed, biomarker analysis of a phase II trial investigating the combination of nivolumab, paclitaxel and bevacizumab in patients with HER2-negative metastatic breast cancer revealed that patients with increased sCD163 after 1 week of treatment had significantly longer PFS compared to patients with sCD163 decrease (mPFS 18.2 vs 13.6 months, HR 0.50 [0.26-0.93], p = 0.0263), with, although not statistically significant, a similar trend in OS (p = 0.0548) [115]. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/1113560365178880-1642504888335_Q64/Yukinori-Ozaki.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/324316699267072-1454334534137_Q64/Shigehisa-Kitano.jpg)
... To date, only 33 cases of breast SFTs, including 5 malignant tumors, have been reported (6). In the present report, a rare case of a 48-year-old female patient with a large tumor confirmed to be a malignant SFT is reported. ...
... Horie et al (64) revealed that the BC Natural antisense transcript 1 (BNAT1) can induce tamoxifen-resistant in ER + BC cells and its silencing significantly reduced the in vitro and in vivo growth of cancer cells. This mechanism is mediated by binding of BNAT1 binding with ERα and its knockdown reduced ERα expression and its transactivation. ...
... Furthermore, the cut-off value of the morphological features of metastatic ALNs was not well-established in the previous literature [11,13,18]. In our experience [19], the presence of LOH caused by metastasis cannot be judged when ALNs are smaller than 4 mm in long-axis diameter. Moreover, as most normal ALNs smaller than 4 mm show a round shape, we measured all ALNs that were at least 3 mm in long-axis diameter, and tried to interpret the cortex structure as closely as possible. ...
... Immunotherapy may be a good treatment option for some BC patients [10,11]. However, only a few cancer patients can benefit from immunotherapy [12]. Increasing evidence indicates that immune infiltration in tumor microenvironment (TME) is a decisive factor in predicting BC prognosis and immunotherapy response [13]. ...
... The paraspeckle component 1 (PSPC1)-Sec1 family domain containing 2 (SCFD2)-DDIAS axis is highly expressed in tamoxifen-resistant breast cancer and is a potential diagnostic and therapeutic target for estrogen receptor (ER)-positive breast cancer 39,40 . PSPC1 is an RNA-binding protein (RBP) belonging to the Drosophila behavior human splicing (DBHS) family and functions as a cancer transcriptional regulator 41,42 . ...
... The up-regulation of TRIM6 expression in BC promoted STIP1 homology and U-Box containing protein 1 (STUB1) degradation through the ubiquitin-dependent proteasome and subsequently activated YAP1 signaling to promote BC growth and migration . TRIM39 knockdown significantly inhibited BC cell proliferation and arrested the cell cycle at S-phase (Ogura et al., 2022). TRIM47 expression was positively correlated with the shortened DFS in patients with postoperative endocrine therapy, and TRIM47 over-expression activated NF-κB signaling, which contributed to the resistance to endocrine therapy in BC (Azuma et al., 2021). ...
... Our ChIP and dual luciferase reporter assays confirmed OCT1 binds the FSTL1 promoter to induce its expression in cSCC cells. As an essential transcription factor, OCT1 plays a crucial role in proliferation, metastasis and metabolism [43][44][45]. For instance, study has showed that OCT1 binds the ALDOA promoter, enhancing activity and metabolic reprogramming to drive progression and drug resistance in colon cancer [43]. ...
